{"id":"W3165793297","doi":"10.1136/annrheumdis-2021-eular.2695","title":"OP0228 EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"Keele University; University of California, San Diego; University of Toronto; University College Dublin; Singapore General Hospital; University of Leeds; Northwell Health; University of Pennsylvania; Cleveland Clinic; University of Washington","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Clinical endpoint; Rheumatology; Placebo; Psoriasis; Adverse effect; Randomized controlled trial; Gastroenterology; Arthritis; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002381528,0.0021503,0.004245785,0.0003684897,0.0005324782,0.001616606,0.0009596134,0.002436715,0.004489902],"category_scores_gemma":[0.002054124,0.0008506585,0.00323562,0.0003359998,0.001370102,0.001545298,0.0005280738,0.003968338,0.001138244],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005332611,"about_ca_system_score_gemma":0.0008116803,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007444946,"about_ca_topic_score_gemma":0.001592799,"domain_scores_codex":[0.9992062,0.0003984699,0.00004685244,0.0001490216,0.00007836278,0.000121097],"domain_scores_gemma":[0.9985356,0.0004850622,0.0003659199,0.0001585956,0.00007789859,0.0003769909],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9785386,0.002962707,0.0009093439,0.0004385053,0.001060989,0.00005453954,0.00005764579,0.0002916874,0.002825262,0.00006313666,0.0007610057,0.01203664],"study_design_scores_gemma":[0.9563824,0.03819792,0.003546006,0.0000209783,0.0006056408,0.00006023353,0.0000262307,0.0003434433,0.0003433583,0.0001379252,0.0003150746,0.00002081462],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909218,0.004558746,0.0003920524,0.0006701833,0.0003184447,0.0006925342,0.001029809,0.0001338747,0.001282454],"genre_scores_gemma":[0.9904212,0.001919448,0.0008638437,0.001163916,0.0005179146,0.0009437108,0.001497975,0.00004431672,0.002627541],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004489902,"threshold_uncertainty_score":0.01502019,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0822944902644143,"score_gpt":0.3282076787436841,"score_spread":0.2459131884792698,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}